# Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

> **NCT04064346** · PHASE3 · TERMINATED · sponsor: **Palladio Biosciences** · enrollment: 12 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney
- ADPKD

## Interventions

- **DRUG:** Lixivaptan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04064346
- **Lead sponsor:** Palladio Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-28
- **Primary completion:** 2022-08-03
- **Final completion:** 2022-08-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with autosomal dominant polycystic kidney disease (ADPKD).
- **Last updated:** 2023-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04064346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04064346, "Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04064346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*